These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 15997131)

  • 21. Synthesis and pharmacological evaluation of 5-(4-biphenyl)-3-methyl-4-phenyl-1,2,4-triazole derivatives as a novel class of selective antagonists for the human vasopressin V(1A) receptor.
    Kakefuda A; Suzuki T; Tobe T; Tsukada J; Tahara A; Sakamoto S; Tsukamoto S
    J Med Chem; 2002 Jun; 45(12):2589-98. PubMed ID: 12036368
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and biological evaluation of substituted desloratadines as potent arginine vasopressin V2 receptor antagonists.
    Mu S; Liu Y; Gong M; Liu DK; Liu CX
    Molecules; 2014 Feb; 19(2):2694-706. PubMed ID: 24566331
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Arginine vasopressin ameliorates spatial learning impairments in chronic cerebral hypoperfusion via V1a receptor and autophagy signaling partially.
    Yang C; Zhang X; Gao J; Wang M; Yang Z
    Transl Psychiatry; 2017 Jul; 7(7):e1174. PubMed ID: 28934194
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Central vasopressin V1A receptor blockade alters patterns of cellular activation and prevents glucocorticoid habituation to repeated restraint stress exposure.
    Gray M; Innala L; Viau V
    Int J Neuropsychopharmacol; 2014 Dec; 17(12):2005-15. PubMed ID: 24913767
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte.
    Tahara A; Tomura Y; Wada K; Kusayama T; Tsukada J; Ishii N; Yatsu T; Uchida W; Tanaka A
    Cardiovasc Res; 1998 Apr; 38(1):198-205. PubMed ID: 9683922
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Vasopressin promotes cardiomyocyte hypertrophy via the vasopressin V1A receptor in neonatal mice.
    Hiroyama M; Wang S; Aoyagi T; Oikawa R; Sanbe A; Takeo S; Tanoue A
    Eur J Pharmacol; 2007 Mar; 559(2-3):89-97. PubMed ID: 17275806
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonpeptide antagonists for vasopressin receptors. Pharmacology of SR 121463A, a new potent and highly selective V2 receptor antagonist.
    Serradeil-Le Gal C
    Adv Exp Med Biol; 1998; 449():427-38. PubMed ID: 10026834
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacological profile of VP-343, a novel selective vasopressin V2 receptor antagonist, in rats.
    Naito A; Ohtake Y; Hasegaw H; Fukaya AY; Kurasawa T; Naito K; Matsukawa H; Oguma T; Ezure Y; Tsuriya Y; Tanaka H; Koike K; Shigenobu K
    Biol Pharm Bull; 2000 Feb; 23(2):182-9. PubMed ID: 10706381
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of arginine vasopressin and oxytocin on glucagon release from clonal alpha-cell line In-R1-G9: involvement of V1b receptors.
    Yibchok-anun S; Hsu WH
    Life Sci; 1998; 63(21):1871-8. PubMed ID: 9825765
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery and Characterization of RGH-122, a Potent, Selective, and Orally Bioavailable V1a Receptor Antagonist.
    Baska F; Bozó É; Szeleczky Z; Szántó G; Vukics K; Szakács Z; Domány-Kovács K; Kurkó D; Vass E; Thán M; Vastag M; Temesvári K; Lévai S; Halász AS; Szondiné Kordás K; Román V; Greiner I; Bata I
    J Med Chem; 2024 Jan; 67(1):643-673. PubMed ID: 38165765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The synthesis and vasopressin (AVP) antagonist activity of a novel series of N-aroyl-2,4,5,6-tetrahydropyrazolo[3,4-d]thieno[3,2-b]azepines.
    Albright JD; Delos Santos EG; Dusza JP; Chan PS; Coupet J; Ru X; Mazandarani H
    Bioorg Med Chem Lett; 2000 Apr; 10(8):695-8. PubMed ID: 10782666
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Synthesis and evaluation of potent and selective human V1a receptor antagonists as potential ligands for PET or SPECT imaging.
    Fabio K; Guillon C; Lacey CJ; Lu SF; Heindel ND; Ferris CF; Placzek M; Jones G; Brownstein MJ; Simon NG
    Bioorg Med Chem; 2012 Feb; 20(3):1337-45. PubMed ID: 22249122
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of oxytocin receptors and vasopressin V1a receptors in uterine contractions in rats: implications for tocolytic therapy with oxytocin antagonists.
    Chan WY; Wo NC; Manning M
    Am J Obstet Gynecol; 1996 Nov; 175(5):1331-5. PubMed ID: 8942510
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synthesis and biological evaluation of novel indoloazepine derivatives as non-peptide vasopressin V2 receptor antagonists.
    Matthews JM; Greco MN; Hecker LR; Hoekstra WJ; Andrade-Gordon P; de Garavilla L; Demarest KT; Ericson E; Gunnet JW; Hageman W; Look R; Moore JB; Maryanoff BE
    Bioorg Med Chem Lett; 2003 Feb; 13(4):753-6. PubMed ID: 12639574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis and structure-activity relationships of amide derivatives of (4,4-difluoro-1,2,3,4-tetrahydro-5H-1-benzazepin-5-ylidene)acetic acid as selective arginine vasopressin V2 receptor agonists.
    Tsukamoto I; Koshio H; Kuramochi T; Saitoh C; Yanai-Inamura H; Kitada-Nozawa C; Yamamoto E; Yatsu T; Shimada Y; Sakamoto S; Tsukamoto S
    Bioorg Med Chem; 2009 Apr; 17(8):3130-41. PubMed ID: 19321349
    [TBL] [Abstract][Full Text] [Related]  

  • 36. N-Methylbenzanilide derivatives as a novel class of selective V(1A) receptor antagonists.
    Kakefuda A; Tsukada J; Kusayama T; Tahara A; Tsukamoto S
    Bioorg Med Chem Lett; 2002 Jan; 12(2):229-32. PubMed ID: 11755361
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Binding of the non-peptide vasopressin V1a receptor antagonist SR-49059 in the rat brain: an in vitro and in vivo autoradiographic study.
    Tribollet E; Raufaste D; Maffrand J; Serradeil-Le Gal C
    Neuroendocrinology; 1999 Feb; 69(2):113-20. PubMed ID: 9986924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vasopressin receptor antagonists: a patent summary (2018-2022).
    Baska F; Bozó É; Patócs T
    Expert Opin Ther Pat; 2023; 33(5):385-395. PubMed ID: 37226495
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Critical role of a subdomain of the N-terminus of the V1a vasopressin receptor for binding agonists but not antagonists; functional rescue by the oxytocin receptor N-terminus.
    Hawtin SR; Wesley VJ; Parslow RA; Patel S; Wheatley M
    Biochemistry; 2000 Nov; 39(44):13524-33. PubMed ID: 11063589
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Non-peptide arginine-vasopressin antagonists: the vaptans.
    Decaux G; Soupart A; Vassart G
    Lancet; 2008 May; 371(9624):1624-32. PubMed ID: 18468546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.